Thank you for noting that the slide deck is dated back to 2012 I’ve learnt a lot! And I’m looking forward to learning from Dr Stahl in the upcoming mental health conference in Abu Dhabi! Psychiatric disorders are not only produced by “bad” genes; they’re also produced by “normal” genes. In psychiatry, symptom suppression doesn’t mean the same thing as it does in other areas of medicine. In psychiatry, the symptom may be the disease and symptom suppression may both improve function and prevent disease progression. We don’t need first line drugs; we need drugs for treatment resistance. First line treatments have already been satisfied through other elements of an MDT service. We resort to drugs when first line treatments don’t work. The future targets of drug interventions lies in affecting changes in cognition, substance abuse and inflammatory and immune dysregulation. Innovation is not dead in psychopharcotherapy. We’re changing The methodologies are changing. New problems are being addressed and the new targets are neurocircuitry underlying symptoms shared by different psychiatric disorders.
Very interesting lecture by Stephen M. Stahl MD. Thank you for posting this lecture video. By Gregg L. Friedman MD
A true genius...the godfather of psychopharmacology
Although this is dated March, 2016, please note that the NEI slide deck has 2012 as the copyright year. :)
Thank you for noting that the slide deck is dated back to 2012
I’ve learnt a lot! And I’m looking forward to learning from Dr Stahl in the upcoming mental health conference in Abu Dhabi!
Psychiatric disorders are not only produced by “bad” genes; they’re also produced by “normal” genes.
In psychiatry, symptom suppression doesn’t mean the same thing as it does in other areas of medicine. In psychiatry, the symptom may be the disease and symptom suppression may both improve function and prevent disease progression.
We don’t need first line drugs; we need drugs for treatment resistance. First line treatments have already been satisfied through other elements of an MDT service. We resort to drugs when first line treatments don’t work.
The future targets of drug interventions lies in affecting changes in cognition, substance abuse and inflammatory and immune dysregulation.
Innovation is not dead in psychopharcotherapy. We’re changing The methodologies are changing. New problems are being addressed and the new targets are neurocircuitry underlying symptoms shared by different psychiatric disorders.
@@naseralriyami2568 oh I'm a lay person but I'm a huge huge fan of Dr S. Stahl!!
what is meant by "information processing efficiency" ?
I appreciate the information you have shared .
Great Stephen!
This is one of the best lectures in this series. Thank you Dr. Stahl.